



MONTHLY REPORT - MARCH 2026

Warsaw, April 2026

TOTAL OPEN MARKET (SELL-OUT REPORT)


	MARCH 2026	CHANGE IN COMPARISON TO			CUMULATIVE YTD	
		FEBRUARY 2026	JANUARY 2026	MARCH 2025	2026	CHANGE VS 2025
TOTAL TURNOVER (PLN MILLION)						
Total open market ¹	5,463	6.7%	1.7%	3.6%	15,957	3.1%
Rx reimbursed ²	1,646	10.4%	6.4%	8.2%	4,684	7.9%
Rx nonreimbursed ³	1,658	9.0%	5.1%	9.0%	4,756	7.6%
Non Rx products ⁴	2,108	2.3%	-4.0%	-3.3%	6,362	-3.3%
REIMBURSEMENT						
Reimbursement value (PLN million)	1,453	11.6%	8.6%	8.4%	4,094	7.9%
Reimbursement share In total turnover	26.6%	4.7%	6.8%	4.6%	25.7%	4.7%
Reimbursement share In reimbursed sales	86.6%	1.3%	2.2%	0.1%	85.7%	0.0%
AVERAGE PRICE PER PACK (PLN)						
Total ¹	35.29	1.4%	2.3%	8.0%	34.87	7.8%
For reimbursed Rx products ²	37.86	0.0%	1.5%	6.6%	37.67	6.7%
For nonreimbursed Rx products ³	48.77	0.7%	1.0%	9.7%	48.51	10.9%
For Non Rx products ⁴	27.45	1.1%	1.2%	5.0%	27.24	4.7%
AVERAGE MARK-UP						
Total ¹	25.7%	2.2%	-2.2%	-3.1%	25.7%	-4.3%
For reimbursed Rx products ²	19.1%	2.3%	2.3%	-3.4%	18.8%	-7.0%
For nonreimbursed Rx products ³	20.6%	-11.4%	-6.6%	-2.5%	21.9%	-0.2%
For Non Rx products ⁴	33.2%	3.0%	2.7%	-2.9%	32.6%	-0.4%
AVERAGE PHARMACY						
Number of patients in pharmacies	4,570	3.2%	2.2%	-2.1%	13,470	-5.1%
Total turnover (PLN thousand) ¹	449	6.8%	2.2%	5.2%	1,309	4.6%

TOTAL PHARMACY TURNOVER CUMULATIVE IN PLN MILLION


2026	PHARMACY MARKET TOTAL ¹		RX REIMBURSED PRESCRIPTIONS ²		RX NONREIMBURSED PRESCRIPTIONS ³		NON RX PRODUCTS ⁴	
	TOTAL	CHANGE VS 2025	TOTAL	CHANGE VS 2025	TOTAL	CHANGE VS 2025	TOTAL	CHANGE VS 2025
January	5,372	1.4%	1,547	6.2%	1,578	4.0%	2,195	-3.4%
February	10,494	2.7%	3,038	7.8%	3,098	6.9%	4,255	-3.3%
March	15,957	3.1%	4,684	7.9%	4,756	7.6%	6,362	-3.3%
April								
May								
June								
July								
August								
September								
October								
November								
December								

TRENDS

TOTAL MONTHLY PHARMACY SALES IN PLN MILLION



TOTAL MONTHLY SALES IN AN AVERAGE PHARMACY IN PLN THOUSAND




AVERAGE PHARMACY

	MARCH'26		YTD'2026		FEBRUARY'26		CHANGE		MARCH'25		CHANGE		YTD'2025		CHANGE	
	VALUE	%	VALUE	%	VALUE	%	VALUE	%	VALUE	%	VALUE	%	VALUE	%	VALUE	%
TOTAL TURNOVER (THOUSAND PLN)																
Total open market ¹	449.0	1,309.0	420.5	28.5	6.8%	427.0	22.0	5.2%	1,252.0	57.0	4.6%					
Rx reimbursed ²	135.3	384.3	122.4	12.9	10.5%	123.3	12.0	9.8%	351.0	33.3	9.5%					
Rx nonreimbursed ³	136.2	390.1	124.8	11.4	9.1%	123.2	13.0	10.6%	357.3	32.9	9.2%					
Non Rx products ⁴	173.2	521.9	169.1	4.1	2.4%	176.7	-3.4	-1.9%	532.1	-10.2	-1.9%					
AVERAGE PRICE⁵ PER PACK (PLN)																
Total ¹	35.29	34.87	34.82	0.47	1.4%	32.68	2.61	0.08	32.35	2.53	7.8%					
For reimbursed Rx products ²	37.86	37.67	37.84	0.02	0.0%	35.50	2.35	0.07	35.31	2.36	6.7%					
For nonreimbursed products ³	48.77	48.51	48.45	0.32	0.7%	44.46	4.31	9.7%	43.74	4.77	10.9%					
For Non Rx products ⁴	27.45	27.24	27.15	0.30	1.1%	26.15	1.30	5.0%	26.03	1.21	4.7%					
AVERAGE MARK-UP*																
Total ¹	25.7%	25.7%	25.1%	0.5%	2.2%	26.5%	-0.8%	-3.1%	26.9%	-1.2%	-4.3%					
For reimbursed Rx products ²	19.1%	18.8%	18.7%	0.4%	2.3%	19.8%	-0.7%	-3.4%	20.2%	-1.4%	-7.0%					
For nonreimbursed Rx products ³	20.6%	21.9%	23.2%	-2.6%	-11.4%	21.1%	-0.5%	-2.5%	21.9%	0.0%	-0.2%					
For Non Rx products ⁴	33.2%	32.6%	32.3%	1.0%	3.0%	34.2%	-1.0%	-2.9%	32.8%	-0.1%	-0.4%					
NUMBER OF PATIENTS																
Total ¹	4,570	13,470	4,430	140	3.2%	4,670	-100	-2.1%	14,190	-720	-5.1%					
For reimbursed Rx products ²	980	2,810	910	70	7.7%	1,030	-50	-4.9%	3,130	-320	-10.2%					
For nonreimbursed Rx products ³	1,170	3,400	1,130	40	3.5%	1,000	170	17.0%	3,040	360	11.8%					
For Non Rx products ⁴	3,630	10,840	3,580	50	1.4%	3,770	-140	-3.7%	11,480	-640	-5.6%					
NUMBER OF PHARMACIES - SUMMARY⁶																
	12,167	12,190	12,181	-14	-0.1%	12,344	-177	-1.4%	12,368	-178	-1.4%					

* Values in „Change – value“ for average mark-up in percentage points


Number of pharmacies based on PEX's analysis, average monthly number of pharmacies

PHARMACIES ON THE OPEN MARKET



PRICE

STRUCTURE OF THE AVERAGE RETAIL PRICE⁵



All amounts are retail open pharmacy sales in PLN

Most important terms:

¹ Total open pharmacy market sales

² Total sales of Rx products covered by NHF reimbursement

³ Total sales of Rx products not covered by NHF reimbursement

⁴ Total sales of products available without prescription, including OTC medicines, food supplements, herbs, patches, medical devices, etc.

⁵ The calculation of the average price is based on products categorized and included in the pharmacy data database operated by PEX and Kamssoft (Omnibus) – they make up 97% of the pharmacy market.

PEX COMMENTARY

The pharmacy market in March 2026 saw sales go close to 5463m PLN. Value of sales compared to March 2025 grew by 192,1m PLN (+3,6%). Compared to February of 2026, sales grew by approximately 340,9m PLN (+6,7%). Turnover of a statistical pharmacy in March 2026 was 449 thousand PLN, this was an increase by 5,2% compared to the same period in 2025.

Compared to the same period of 2025 the value of tracked segments grew for two monitored segments. Sales based on reimbursed prescriptions grew by 124,4m PLN (+8,2%), sales based on non-reimbursed prescriptions grew by 136,6m PLN (+9%), the non-prescription segment fell by 72,8m PLN (-3,3%).

Compared to the previous month, the value of tracked segments grew for all monitored segments. Value of reimbursed prescriptions grew by 154,6m PLN (+10,4%), value of non-reimbursed RX drugs grew by 137,1m PLN (+9%) and value of products sold without a prescriptions grew by 47,9m PLN (+2,3%).

The average retail drug price in March 2026 was 35,29 PLN and was 1,4% higher than the average price in the previous month, and 8% higher than the average price in March 2025. The average retail price of reimbursed prescription was 37,86 PLN (+6,6% vs March 2025), 48,77 PLN for non-reimbursed prescriptions (+9,7% vs March 2025) and 27,45 PLN for products sold without a prescription (+5% vs March 2025).


Average pharmacy margin for all drugs in March 2026 was 25,7% and was lower by 3,1% than margin in the same period of 2025. Compared to February 2026, the average pharmacy margin was higher by 2,2%.

Drug reimbursement by the National Health Fund in March was in the amount 1453m PLN, 8,4% more than in the same period of 2025. The level of patient copayment for reimbursed drugs in March was 13,4%, fell by 1,1p.p. compared to previous month and fell by 0,1p.p. compared to the same period in 2025.

ABOUT US

PEX is a Polish **consulting and research company** with its own wide-ranging resources of market data. We specialize in services for entities operating in the broadly defined healthcare market.

As a result of numerous projects, carried out over **almost 20 years** of the company's operations on the Polish market, for innovative, generic, and OTC producers, PEX PharmaSequence has gained unique expertise that allows us to provide our Clients with valuable support.



It is not without significance that our team, comprising **50+ people**, has the benefit of experience gained in service companies specializing in the pharma sector, as well as industry experience acquired in local and global pharmaceutical companies.

Our expertise and competencies as well as our **knowledge of the Polish pharma market** enable us to develop proposals and efficiently carry out projects, which offer added value to our Clients' business decisions.

WE WOULD LIKE TO HEAR FROM YOU



www.pexps.pl more info



Ask us a question:
solutions_by_pex@pexps.pl
 22 886 47 15

Published on the 16th of April 2026,
 prepared by Martyna Janus
 based on PEX data.

The copyright to this document belongs to PEX Sp. z o.o., headquartered in Warsaw. The contents of this document are not a result of a provided service and PEX Sp. z o.o. is not responsible to third parties using this document, on any legal basis, for any action taken or not taken, including for decisions made based on information provided. Quoting parts of the document requires indicating PEX Sp. z o.o. as the author.

PEX Sp. z o.o.
ul. Migdałowa 4D lok. 46, 02-796 Warszawa
tel.: (+48) 22 886 47 15
fax (+48) 22 638 21 29
biuro@pexps.pl

